CENTRE LEON BERARD

Patent Owner

Watch Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology Matters Rank in Class
 
  
 
C07K PEPTIDES 6130
 
  
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 5250
 
  
 
G01N INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 4202
 
  
 
C12Q MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS 2123
 
  
 
A61B DIAGNOSIS; SURGERY; IDENTIFICATION 1239
 
  
 
A61D VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS113
 
  
 
A61M DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY 1153
 
  
 
A61N ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY 1106
 
  
 
C12N MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF 1166
 
  
 
G10K SOUND-PRODUCING DEVICES 134

Top Patents (by citation)

Upgrade to the Professional Level to View Top Patents for this Owner. Learn More

Recent Publications

Publication # Title Filing Date Pub Date Intl Class
2017/0342,499 GENOMIC CLASSIFIER THAT PREDICTS RESPONSE TO MULTI-KINASE INHIBITOR TREATMENT INTRODUCTIONDec 18, 15Nov 30, 17[C12Q]
2016/0369,242 METHOD FOR PRODUCING INDUCED PLURIPOTENT CELLSJan 13, 15Dec 22, 16[C12N]
2015/0004,159 SCREENING FOR ANTI-CANCER COMPOUNDS USING NETRIN-1 ACTIVITYSep 15, 14Jan 01, 15[C07K]

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
9695247 Antibodies directed against ICOS for treating graft-versus-host diseaseSep 03, 13Jul 04, 17[A61K, C07K]
9683986 Treatment of cancer by inhibition of the MYD88/ERK MAP kinase interactionDec 17, 12Jun 20, 17[C12Q, G01N]
9676852 Antibodies directed against ICOS and uses thereofMay 26, 16Jun 13, 17[A61K, G01N, C07K]
9376493 Antibodies directed against ICOS and uses thereofMar 29, 12Jun 28, 16[A61K, G01N, C07K]

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
2015/0250,770 LKB1 AS PREDICTIVE MARKER OF EVEROLIMUS EFFICACY IN BREAST CANCERAbandonedJul 01, 13Sep 10, 15[A61K, G01N]
2015/0212,087 Detection of the ERalpha/Src/PI3K Complex as Predictive Marker in Breast CancerAbandonedJul 26, 13Jul 30, 15[G01N]
2014/0186,364 INHIBITION OF THE NT-3:TRKC BOUND AND ITS APPLICATION TO THE TREATMENT OF CANCER SUCH AS NEUROBLASTOMAAbandonedDec 19, 13Jul 03, 14[A61K, C07K]
2014/0155,470 PLA2R1 AS ANTI-TUMORAL COMPOUND AND AS BIOMARKER FOR THE DETECTION OF CANCERAbandonedJul 06, 12Jun 05, 14[A61K, C07K]
2013/0084,564 ASSESSMENT OF CANCER RISK BASED ON RNU2 CNV AND INTERPLAY BETWEEN RNU2 CNV AND BRCA1AbandonedJun 01, 12Apr 04, 13[C12Q]
2012/0309,013 Use of the Combinatorial Diversity of T-Lymphocyte Repertoire as a Prognostic Marker of CancerAbandonedDec 09, 10Dec 06, 12[G01N]
2012/0220,487 Determination of 17q Gain in Neuroblastoma Patients by Analysis of Circulating DNAAbandonedNov 02, 10Aug 30, 12[C12Q, C40B]
2012/0076,788 C-CBL AND ANTAGONISTS THEREOF FOR THE TREATMENT AND DIAGNOSIS OF CANCERAbandonedFeb 10, 10Mar 29, 12[A61K, C12Q, G01N, A61P]
2012/0015,364 METHOD FOR THE SELECTION OF ENDOTHELIAL CELLS DEATH INDUCERS VIA NETRIN-1 AND ITS APPLICATIONSAbandonedJan 11, 10Jan 19, 12[C07H, C12Q, G01N, C07K]
2011/0229,485 INHIBITION OF THE NT-3:TRKC BOUND AND ITS APPLICATION TO THE TREATMENT OF CANCER SUCH AS NEUROBLASTOMAAbandonedMay 22, 09Sep 22, 11[A61K, C07H, C12Q, G01N, A61P, C07K]
2009/0226,458 Screening For Anti-Cancer Compounds Using Netrin-1 ActivityAbandonedFeb 28, 07Sep 10, 09[A61K, C12Q, G01N, C07K]
7414024 Proteins with IL-6 inhibiting activityExpiredDec 04, 02Aug 19, 08[A61K]
2006/0263,784 Method for the diagnosis/prognosis of neuroblastomaAbandonedOct 01, 04Nov 23, 06[C12Q, C12M]

Top Inventors for This Owner

Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!

We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.